A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model

References

• Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899–1912
   PubMed Web of Science ®Google Scholar
• Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011;35:596–610
   PubMed Web of Science ®Google Scholar
• Clark RA. Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol 2010;130:362–370
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129:1339–1350
   PubMed Web of Science ®Google Scholar
• Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009;129:79–88
   PubMed Web of Science ®Google Scholar
• Guilhou JJ. The therapeutic effects of vitamin D3 and its analogues in psoriasis. Expert Opin Investig Drugs 1998;7:77–84
   Google Scholar
• Nast A, Kopp IB, Augustin M, et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Deutsh Dermatol Ges 2007;5:1–119
   PubMedGoogle Scholar
• Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23:1–70
   PubMed Web of Science ®Google Scholar
• van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009;182:5836–5845
   PubMed Web of Science ®Google Scholar
• Farahani SS, Navabazam A, Ashkevari FS. Comparison of mast cells count in oral reactive lesions. Pathol Res Pract 2010;206:151–155
   PubMed Web of Science ®Google Scholar
• Mahaisavariya P, Jiamton S, Manonukul J, Khemngern S. Mast cells in leprosy and leprosy reaction. Int J Dermatol 2000;39:274–277
   PubMed Web of Science ®Google Scholar
• Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004;51:547–555
   PubMed Web of Science ®Google Scholar
• Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002;47:390–398
   PubMed Web of Science ®Google Scholar
• Palamara F, Meindl S, Holcmann M, et al. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004;173:3051–3061
   PubMed Web of Science ®Google Scholar
• Fujisawa H, Shivji GM, Kondo S, et al. Effect of a novel topical immunomodulator, S-28463, on keratinocyte cytokine gene expression and production. J Interferon Cytokine Res 1996;16:555–559
   PubMed Web of Science ®Google Scholar
• Kono T, Kondo S, Pastore S, et al. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res 1994;13:71–76
   PubMedGoogle Scholar
• Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007;122:201–206
   PubMed Web of Science ®Google Scholar
• Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273–290
   PubMed Web of Science ®Google Scholar
• Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14:155–174
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 2002;71:1–8
   PubMed Web of Science ®Google Scholar
• Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467–476
   PubMed Web of Science ®Google Scholar
• Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med 2000;191:1233–1240
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126:1121–1133
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519–550
   PubMed Web of Science ®Google Scholar
• Roark CL, Simonian PL, Fontenot AP, et al. Gammadelta T cells: an important source of IL-17. Current Opin Immunol 2008;20:353–357
   PubMed Web of Science ®Google Scholar
• Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130:1373–1383
   PubMed Web of Science ®Google Scholar
• Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol 2001;2:95–120
   PubMedGoogle Scholar
• Muller K, Svenson M, Bendtzen K. 1α,25-Dihydroxyvitamin D3 and a novel vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 in vitro. Immunol Lett 1988;17:361–365
   PubMed Web of Science ®Google Scholar
• Muller K, Diamant M, Bendtzen K. Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. Immunol Lett 1991;28:115–120
   PubMed Web of Science ®Google Scholar
• Frohman EM, Frohman TC, Dustin ML, et al. The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-gamma, tumor necrosis factor alpha, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentation. J Neuroimmunol 1989;23:117–124
   PubMed Web of Science ®Google Scholar
• Lin XR, Huang TA, Yang CM, et al. Clinical trial and experimental study on treating psoriasis with camptothecine. Chinese Med J 1988;101:427–430
   PubMed Web of Science ®Google Scholar
• Lin XR, Huang T. Topical camptothecine in treatment of psoriasis. Int J Dermatol 1988;27:475–476
   PubMed Web of Science ®Google Scholar
• Sun J, Han J, Zhu Q, et al. Camptothecin fails to induce apoptosis in tumor necrosis factor-alpha-treated HaCaT cells. Pharmacology 2012;89:58–63
   PubMed Web of Science ®Google Scholar
• Duvic M, Nagpal S, Asano AT, Chandraratna RA. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997;37:S18–S24
   PubMed Web of Science ®Google Scholar
• Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005;11:43–49
   PubMed Web of Science ®Google Scholar